Back to top
more

ClearPoint Neuro (CLPT)

(Delayed Data from NSDQ)

$15.17 USD

15.17
421,960

-0.22 (-1.43%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $15.07 -0.10 (-0.66%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 247)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -5.00% and -10.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of +25.00% and -3.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Integra LifeSciences (IART) Q3 Earnings Beat Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of +25.58% and -3.07%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TransMedics (TMDX) Beats Q3 Earnings Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of +78.38% and -0.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CLPT Expands Into Robotic System Supporting Cell and Gene Therapies

by Zacks Equity Research

ClearPoint's new Robotic Neuro-Navigation System merges proven software with KUKA robotics to boost precision in cell and gene therapy delivery.

Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -5.00% and -3.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

RxSight (RXST) delivered earnings and revenue surprises of +20.00% and +0.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Nalak Das headshot

5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil

by Nalak Das

Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.

Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -46.67% and 2.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Believe ClearPoint Neuro (CLPT) Could Rally 102.86%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 102.9% in ClearPoint Neuro (CLPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.